N-803 has also been shown to increase PD-L1 expression both in vitro (22) and in breast tumor-bearing mice (23); it has been suggested that this may allow lymphocytes to become targets of anti-PD-L1 therapy. This evidence concerns the gene CD274 and breast neoplasm.